UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?

Lorenzo-Vizcaya, A; Fasano, S; Isenberg, DA; (2020) Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE? ImmunoTargets and Therapy , 9 pp. 105-110. 10.2147/ITT.S240874. Green open access

[thumbnail of itt-240874-bruton-rsquo-s-tyrosine-kinase-inhibitors-xfeff-a-new-the.pdf]
Preview
Text
itt-240874-bruton-rsquo-s-tyrosine-kinase-inhibitors-xfeff-a-new-the.pdf - Published Version

Download (248kB) | Preview

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease with a complex pathogenesis, which presents a great variability in its presentation and can affect almost all organs and systems. Multiple therapeutic targets have been discovered recently, but there also have been failed attempts to treat SLE using biologic agents. Bruton’s tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase expressed in several types of cells of hematopoietic origin which participate in both innate and adaptive immunity. Ibrutinib, a BTK inhibitor, is approved for the treatment of several B cell malignancies, including some types of lymphoma and leukemia. As BTK is expressed on several immune cell types, the mechanism of action of BTK also suggests the use of BTK inhibitors in the treatment of autoimmune diseases. In this review, we will summarize what is known and what has been published so far about the treatment of mouse models of SLE and the human disease, using BTK inhibitors.

Type: Article
Title: Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
Location: New Zealand
Open access status: An open access version is available from UCL Discovery
DOI: 10.2147/ITT.S240874
Publisher version: https://doi.org/10.2147/ITT.S240874
Language: English
Additional information: This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. https://creativecommons.org/licenses/by-nc/3.0/
Keywords: lupus, Bruton, tyrosine kinase, therapeutic targeting, ibrutinib, fenebrutinib
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10110500
Downloads since deposit
47Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item